OpenAlex 4,089 works 117 author topics
Works
4,089 works
-
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. METHODS: We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.8%
The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morp…
-
Bladder cancer 2017YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
No abstract yet.
-
OpenAlex top 1%
OpenAlex 100.0%
No abstract yet.
-
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy. METHODS: In this phase 3, multinational, open-label trial, we randomly assigned patients with previously untreated unresectable or metastatic ur…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.1%
PURPOSE: There are significant differences in clinicopathological features among renal cell carcinoma histological subtypes but controversy exists regarding the independent impact of histological subtype on patient outcome after nephrectomy. We examined the significance of histological subtype on progression to distan…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.8%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.8%
No abstract yet.
Academicians
117 academicians
- JOHAN JOSEPH MARIA CATHARINA HUBERTUS DELAROSETTE 147 author topics
- SÜMER BALTACI 76 author topics
- YÜKSEL ÜRÜN 49 author topics
- İLKER TİNAY 46 author topics
- NECMETTİN AYDIN MUNGAN 26 author topics
- MURAT KURT 22 author topics
- EMİNE BURÇİN TUNA 21 author topics
- EVREN SÜER 21 author topics
- OKTAY AKÇA 21 author topics
- BAHRİ GÖK 20 author topics
- ÇETİN DEMİRDAĞ 20 author topics
- TEVFİK MURAT KOŞAN 20 author topics